Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial

被引:34
作者
Boonstra, Geartsje [1 ]
Burger, Huibert [1 ,3 ]
Grobbee, Diederick E. [2 ]
Kahn, Rene S. [4 ]
机构
[1] UMCU, Dept Adult Psychiat, Rudolf Magnus Inst Neurosci RMI, Dept Psychiat, NL-3584 CX Utrecht, Netherlands
[2] UMCU, Julius Ctr Hlth Sci & Primary Care, Dept Clin Epidemiol, Utrecht, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 AV Groningen, Netherlands
[4] UMCU, RMI, Dept Adult Psychiat, NL-3584 CX Utrecht, Netherlands
关键词
First episode; schizophrenia; pyschopharmacology; antipsychotics; NEGATIVE SYNDROME SCALE; 15-YEAR FOLLOW-UP; MAINTENANCE TREATMENT; NATURAL COURSE; MEDICATION; DISORDERS; RELAPSE; RELIABILITY; VALIDITY; PLACEBO;
D O I
10.3109/13651501.2010.534801
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective. To assess the effect of withdrawal of antipsychotic treatment on relapse risk in remitted first-episode schizophrenia patients. Methods. First-episode 1-year stable and remitted outpatients with a schizophrenic disorder were randomly allocated to continuation of their antipsychotic regimen for at least 6 months (N == 9), or gradual withdrawal (N == 11). Primary outcome was the difference in cumulative relapse-free survival at 9 months. Results. Recruitment was terminated prematurely on 26 October 2005. The cumulative relapse-free survival was 88% (SE == 0.12) in the continuation and 18% (SE == 0.12) in the discontinuation group (P == 0.001) at 9 months follow-up. Conclusions. Discontinuation of antipsychotic medication markedly increases the risk of relapse in stable remitted first-episode schizophrenia patients. In future studies the topics of safety monitoring and sampling of patients should receive extra attention.
引用
收藏
页码:128 / 134
页数:7
相关论文
共 27 条
[1]  
Boonstra N, 2008, Tijdschr Psychiatr, V50, P637
[2]  
CARPENTER WT, 1990, AM J PSYCHIAT, V147, P1138
[3]   Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine [J].
Chrzanowski, Wlodzimierz K. ;
Marcus, Ronald N. ;
Torbeyns, Anne ;
Nyilas, Margaretta ;
McQuade, Robert D. .
PSYCHOPHARMACOLOGY, 2006, 189 (02) :259-266
[4]   THE NORTHWICK PARK STUDY OF 1ST EPISODES OF SCHIZOPHRENIA .2. A RANDOMIZED CONTROLLED TRIAL OF PROPHYLACTIC NEUROLEPTIC TREATMENT [J].
CROW, TJ ;
MACMILLAN, JF ;
JOHNSON, AL ;
JOHNSTONE, EC .
BRITISH JOURNAL OF PSYCHIATRY, 1986, 148 :120-127
[5]  
Davis J.M., 1993, ANTIPSYCHOTIC DRUGS, P183
[6]  
Dellva MA, 1997, PSYCHIATR SERV, V48, P1571
[7]  
ENGELHARDT DM, 1967, ARCH GEN PSYCHIAT, V16, P98
[8]  
First M.B., 2016, SCID-5-CV: Structured clinical interview for DSM-5 disorders: Clinician version
[9]  
GILBERT PL, 1995, ARCH GEN PSYCHIAT, V52, P173
[10]   Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia [J].
Gitlin, M ;
Nuechterlein, K ;
Subotnik, KL ;
Ventura, J ;
Mintz, J ;
Fogelson, DL ;
Bartzokis, G ;
Aravagiri, M .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (11) :1835-1842